[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629090":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":56,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":25,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Yuhan Corporation","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"A (RT)","EXPERIMENTAL","30 subjects, Cross-over, Single dose YHP2511A on period 1, Single dose of YHP2511 on period 2",[13,14],"Drug: YHP2511","Drug: YHP2511A",{"label":16,"type":10,"description":17,"interventionNames":18},"B (TR)","30 subjects, Cross-over, Single dose YHP2511 on period 1, Single dose of YHP2511A on period 2",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","YHP2511","Test drug: YHP2511, Comparator: YHP2511A",[9,16],null,{"type":21,"name":27,"description":23,"armGroupLabels":28,"otherNames":25},"YHP2511A",[9,16],[30],{"name":31,"affiliation":32,"role":33},"Seoung Hyun Kang","H Plus Yangji Hospital","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Yujin Kim","CONTACT","82-2-828-0394","clinicaltrials@yuhan.co.kr",[41],{"facility":32,"status":42,"city":43,"state":25,"zip":44,"country":45,"countryCode":25,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Seoul","08779","South Korea",{"type":47,"coordinates":48},"Point",[49,50],126.9784,37.566,{"lat":50,"lon":49},[53],{"name":31,"role":37,"phone":54,"phoneExt":25,"email":55},"82-70-4665-6760","juspa@newyjh.com",{"type":57,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100629090","phase-1-bioequivalence-be-study-between-yhp2511-and-yhp2511a-in-healthy-volunteers-100629090",false,"NCT07470125","Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of YHP2511 With YHP2511A in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Adults aged 19 to 55 years at the time of screening visit.\n* Those whose weight is ≥ 50 kg (≥ 45 kg for females) and their body mass index (BMI) shall be between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2\n* Those without clinically significant congenital or chronic diseases at the screening visit and without any pathological symptom or opinion after an internal medicine examination\n* Those who express their voluntary consent to participate in the trial by signing a written consent\n\nExclusion Criteria:\n\n* Those who have participated in a bioequivalence study or other clinical trials and have been administered with investigational products in 6 months prior to the first administration.\n* Others who are judged ineligible to participate in the trial by the principal investigator\n* Female volunteers who are pregnant, suspected to be pregnant or breastfeeding.",true,"ALL","19 Years","55 Years",{"count":70,"type":71},60,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2511 and YHP2511A in healthy volunteers",[77],"Healthy Subjects","2026-05-28",{"date":80,"type":81},"2026-06-02","ACTUAL",{"date":83,"type":71},"2026-06-23",{"date":85,"type":71},"2026-07-11",{"name":5,"class":6},1]